Apyrase protects against allergic airway inflammation by decreasing the chemotactic migration of dendritic cells in mice

Li,Ping; Cao,Jie; Chen,Yifei; Wang,Wei; Yang,Jiong

doi:10.3892/ijmm.2014.1771

Apyrase protects against allergic airway inflammation by decreasing the chemotactic migration of dendritic cells in mice

Authors:
- Ping Li
- Jie Cao
- Yifei Chen
- Wei Wang
- Jiong Yang
View Affiliations

Affiliations: Department of Pneumology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: May 6, 2014 https://doi.org/10.3892/ijmm.2014.1771
Pages: 269-275

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have demonstrated that extracellular adenosine 5'-triphosphate (eATP) is involved in allergic airway inflammation by activating purinergic receptors. eATP can be hydrolyzed by ectonucleotidases, such as CD39. In this study, we investigated the expression and distribution of CD39 in the lungs of mice, as well as the effects of apyrase on airway inflammation and the chemotactic migration of dendritic cells (DCs). A mouse model of asthma was developed with chicken ovalbumin (OVA)/aluminum hydroxide using female C57BL/6 mice. Apyrase was administered to OVA-sensitized mice prior to each challenge by intraperitoneal injection. The distribution of CD39 was detected by immunofluorescence. The mRNA and protein expression of CD39 was determined by quantitative PCR and western blot analysis, respectively. The levels of Th2 cytokines in the bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA). The effect of apyrase on the chemotactic migration of DCs towards ATP was explored by migration assay in vitro. In the lungs, CD39 was primarily located in the cytoplasm and cytomembrane of bronchial epithelial cells and CD39 expression was reduced in mice with allergic asthma. Treatment with apyrase markedly attenuated OVA-induced airway inflammation, including peribronchial eosinophilic inflammation and reduced the number of inflammatory cells, as well as the levels of cytokines in BALF. Furthermore, apyrase also markedly reduced the expression of GATA binding protein 3 (GATA3) and decreased the chemotactic migration of DCs towards ATP.Our data demonstrate that a reduction in CD39 expression may be associated with the development of allergic airway inflammation and that apyrase alleviates airway inflammation by decreasing the chemotactic migration of DCs towards eATP. Therefore, targeting at eATP or ectonucleotidases may provide a novel therapeutic approach for allergic asthma.

View Figures

View References

1	Lloyd CM and Hessel EM: Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immun. 10:838–848. 2010. View Article : Google Scholar : PubMed/NCBI
2	Adcock IM, Caramori G and Chung KF: New targets for drug development in asthma. Lancet. 372:1073–1087. 2008. View Article : Google Scholar : PubMed/NCBI
3	Holgate ST and Polosa R: Treatment strategies for allergy and asthma. Nat Rev Immunol. 8:218–230. 2008. View Article : Google Scholar
4	Lambrecht BN and Hammad H: Biology of lung dendritic cells at the origin of asthma. Immunity. 31:412–424. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kim HY, DeKruyff RH and Umetsu DT: The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 11:577–584. 2010. View Article : Google Scholar : PubMed/NCBI
6	Trautmann A: Extracellular ATP in the immune system: more than just a ‘danger signal’. Sci signal. 2:pe62009.
7	Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K and Enjyoji K: Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 31:217–233. 2005. View Article : Google Scholar : PubMed/NCBI
8	Idzko M, Hammad H, van Nimwegen M, et al: Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 13:913–919. 2007. View Article : Google Scholar : PubMed/NCBI
9	Müller T, Robaye B, Vieira RP, et al: The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy. 65:1545–1553. 2010.PubMed/NCBI
10	Müller T, Vieira RP, Grimm M, et al: A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol. 44:456–464. 2011.PubMed/NCBI
11	Manthei DM, Jackson DJ, Evans MD, et al: Protection from asthma in a high-risk birth cohort by attenuated P2X(7) function. J Allergy Clin Immunol. 130:496–502. 2012. View Article : Google Scholar : PubMed/NCBI
12	Crikis S, Lu B, Murray-Segal LM, et al: Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant. 10:2586–2595. 2010. View Article : Google Scholar : PubMed/NCBI
13	Künzli BM, Berberat PO, Dwyer K, et al: Variable impact of CD39 in experimental murine colitis. Dig Dis Sci. 56:1393–1403. 2011.PubMed/NCBI
14	Künzli BM, Nuhn P, Enjyoji K, et al: Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology. 134:292–305. 2008.PubMed/NCBI
15	Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB and Robson SC: CD39 and control of cellular immune responses. Purinergic Signal. 3:171–180. 2007. View Article : Google Scholar : PubMed/NCBI
16	Deaglio S and Robson SC: Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol. 61:301–332. 2011. View Article : Google Scholar : PubMed/NCBI
17	Antonioli L, Pacher P, Vizi ES and Haskó G: CD39 and CD73 in immunity and inflammation. Trends Mol Med. 19:355–367. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kwak YG, Song CH, Yi HK, et al: Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest. 111:1083–1092. 2003. View Article : Google Scholar : PubMed/NCBI
19	Idzko M, Dichmann S, Ferrari D, et al: Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood. 100:925–932. 2002. View Article : Google Scholar
20	Enjyoji K, Sévigny J, Lin Y, et al: Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 5:1010–1017. 1999. View Article : Google Scholar : PubMed/NCBI
21	Kapojos JJ, van den Berg A, Borghuis T, et al: Enhanced ecto-apyrase activity of stimulated endothelial or mesangial cells is downregulated by glucocorticoids in vitro. Eur J Pharmacol. 501:191–198. 2004. View Article : Google Scholar : PubMed/NCBI
22	Heine P, Braun N, Sévigny J, Robson SC, Servos J and Zimmermann H: The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2. Eur J Biochem. 268:364–373. 2001. View Article : Google Scholar : PubMed/NCBI
23	Paletta-Silva R and Meyer-Fernandes JR: Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases. J Trop Med. 2012:6508742012. View Article : Google Scholar : PubMed/NCBI
24	Souza Vdo C, Schlemmer KB, Noal CB, et al: E-NTPDase and E-ADA activities are altered in lymphocytes of patients with indeterminate form of Chagas’ disease. Parasitol Int. 61:690–696. 2012.PubMed/NCBI
25	Fan J, Zhang Y, Chuang-Smith ON, et al: Ecto-5′-nucleotidase: a candidate virulence factor in Streptococcus sanguinis experimental endocarditis. PloS One. 7:e380592012.
26	Théâtre E, Frederix K, Guilmain W, et al: Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation. J Immunol. 189:1966–1974. 2012.PubMed/NCBI
27	Fletcher JM, Lonergan R, Costelloe L, et al: CD39⁺Foxp3⁺ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 183:7602–7610. 2009.PubMed/NCBI
28	Moncrieffe H, Nistala K, Kamhieh Y, et al: High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol. 185:134–143. 2010. View Article : Google Scholar : PubMed/NCBI
29	Peelen E, Damoiseaux J, Smolders J, et al: Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. J Neuroimmunol. 240–241:97–103. 2011.PubMed/NCBI
30	Hart ML, Gorzolla IC, Schittenhelm J, Robson SC and Eltzschig HK: SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol. 184:4017–4024. 2010. View Article : Google Scholar
31	Bönner F, Borg N, Burghoff S and Schrader J: Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PloS One. 7:e347302012.PubMed/NCBI
32	Friedman DJ, Künzli BM, A-Rahim YI, et al: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Nat Acad Sci USA. 106:16788–16793. 2009. View Article : Google Scholar
33	Chen X, Gao YD and Yang J: Elevated interferon regulatory factor 4 levels in patients with allergic asthma. J Asthma. 49:441–449. 2012. View Article : Google Scholar : PubMed/NCBI
34	Stellato C, Gubin MM, Magee JD, et al: Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR. J Immunol. 187:441–449. 2001. View Article : Google Scholar : PubMed/NCBI